Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder with a selective loss of dopaminergic neurons in the substantia nigra. Evidence suggests oxidation of dopamine (DA) to DA quinone and consequent oxidative stress as a major factor contributing to this vulnerability. We have previously observed that exposure to or induction of NAD(P)H:quinone reductase (QR1), the enzyme that catalyzes the reduction of quinone, effectively protects DA cells. Sulforaphane (SF) is a drug identified as a potent inducer of QR1 in various non-neuronal cells. In the present study, we show that SF protects against compounds known to induce DA quinone production (6-hydroxydopamine and tetrahydrobiopterin) in DAergic cell lines CATH.a and SK-N-BE(2)C as well as in mesencephalic DAergic neurons. SF leads to attenuation of the increase in protein-bound quinone in tetrahydrobiopterin-treated cells, but this does not occur in cells that have been depleted of DA, suggesting involvement of DA quinone. SF pretreatment prevents membrane damage, DNA fragmentation, and accumulation of reactive oxygen species. SF causes increases in mRNA levels and enzymatic activity of QR1 in a dose-dependent manner. Taken together, these results indicate that SF causes induction of QR1 gene expression, removal of intracellular DA quinone, and protection against toxicity in DAergic cells. Thus, this major isothiocyanate found in cruciferous vegetables may serve as a potential candidate for development of treatment and/or prevention of PD.
Footnotes
-
This work was supported by the Brain Research Center of the 21st Century Frontier Research Program (M103KV010011-06K2201-01110), the Korea Research Foundation (KRF-2006-J00800), and the Korea Health 21 R&D Project (A05-0242-A21018-06A2–00010A), Republic of Korea (to O.H)
-
J.M.H. and Y.J.L. contributed equally to this work
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.106.110866.
-
ABBREVIATIONS: PD, Parkinson's disease; DA, dopamine; QR1, NAD(P)H:quinone reductase; SF, sulforaphane, 4-methylsulfinylbutyl isothiocyanate; BH4, tetrahydrobiopterin; 6-OHDA, 6-hydroxydopamine; FBS, fetal bovine serum; MPP+, N-methyl-4-phenylpyridinium; AMPT, α-methyl-p-tyrosine, DCPIP, 2,6-dichlorophenolindophenol; DCFH-DA, dichlorodihydrofluorescein diacetate; NBT, nitroblue tetrazolium; TH, tyrosine hydroxylase; MAP-2, microtubule-associated protein 2; PBS; phosphate-buffered saline; LDH, lactate dehydrogenase; ROS, reactive oxygen species; RT, reverse transcription; PCR, polymerase chain reaction.
- Received July 14, 2006.
- Accepted January 25, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|